3Q sales preview, page-7

IMHO I still see China as a nothing burger either in being a massive purchaser or a producer for ues in the states, maybe for elsewhere never the US which is just my opinion.

At the end of the day ReCell have enough coming in the next 9-12 months that it will get to where it needs to be and be gobbled up, which will be my exit stage left.

But by all accounts if China were such a great market and this PR in 2016 surely pointed to things being that way, Avita should have sold 10's of millions in China just in Vitligo by now.

I hang my hat on the US market, not because I am an American it's just where the money/market is. Hopefully I am wrong about China, we will see.

“This is another important step in delivering our regenerative medicine to where it’s needed,”: said Avita CEO Adam Kelliher. “China has many vitiligo patients, and we know that particularly for acute cases, our approach can bring real benefit. We need the right partners to reach this patient group, and we believe we have such a partner in the Borun Group.”

The Borun Group is one of China’s leaders in vitiligo treatment, and it runs 23 hospitals and employs 138 clinicians specialising in the treatment of vitiligo. It began employing the ReCell® method in 2014 and now uses it in ten of its hospitals. The Borun Group expects more than 300,000 visits from vitiligo patients in China this year, and said it typically deploys ReCell® for acute cases.

“The excellent presentations about how ReCell® can be wisely used for large-area vitiligo patients make us more confident to include ReCell® surgical treatment as a routine therapy in all vitiligo hospitals of our group,” said Borun Group Director Zhongping Meng. “Many thanks to ReCell for bringing benefit to more and more Chinese vitiligo patients.“